|
0
|
|
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Inhibiting STAT1 Signaling and MHC Class I Expression.
(jci.org)
|
Theivanthiran B
…
Hanks BA
Journal of Clinical Investigation
2026-08-13
|
#cancer
#immunotherapy
#amr
#mhc
#inflammasome
|
|
0
|
|
UV irradiation drives lineage-specific MITF-mediated transcription of PD-L1 to confer immune tolerance to UV-mutated melanocytes.
(linkinghub.elsevier.com)
|
Lo JA
…
Fisher DE
Immunity
2026-08-13
|
#melanoma
#immunotolerance
#transcription
#uv-exposure
#immunotherapy
|
|
0
|
|
EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery.
(linkinghub.elsevier.com)
|
Liu L
…
Wang J
Cancer Cell
2026-08-13
|
#cancer
#immunotherapy
#drug delivery
#targeted therapy
#egfr
|
|
0
|
|
Predicting specificity of TCR-pMHC interactions using machine-learning and biophysical models.
(linkinghub.elsevier.com)
|
Culka M
…
AlQuraishi M
Cell Systems
2026-08-13
|
#machine learning
#immunology
#prediction
#protein structure
#immunotherapy
|
|
0
|
|
Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer.
(linkinghub.elsevier.com)
|
Cai YW
…
Yu KD
Cell Reports Medicine
2026-08-13
|
#proteomics
#cancer
#immunotherapy
#biomarker
#amr
|
|
0
|
|
Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria.
(science.org)
|
Steel RWJ
…
Boddey JA
Science
2026-08-13
|
#malaria
#vaccination
#immunity
#attenuation
#immunotherapy
|
|
0
|
|
Histone H3K27M variants determine myeloid subset dependencies and immune reprogramming in diffuse midline glioma.
(pnas.org)
|
Puigdelloses Vallcorba M
…
Hambardzumyan D
PNAS
2026-08-13
|
#glioma
#immunotherapy
#myeloid
#crispr
#microenvironment
|
|
0
|
|
STING agonist profiling by nucleotide library defines structural determinants of cyclic dinucleotide recognition.
(linkinghub.elsevier.com)
|
Bekere I
…
de Oliveira Mann CC
iScience
2026-08-13
|
#immunotherapy
#sting
#innate immunity
#drug design
#ligand-binding
|
|
0
|
|
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.
(linkinghub.elsevier.com)
|
Li ZM
…
Lu S
Cancer Cell
2026-08-13
|
#cancer
#lung
#clinical trial
#immunotherapy
#toxicity
|